Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Henry Khederian

Why Clarus Therapeutics Shares Are Getting Hammered

Clarus Therapeutics Holdings Inc (NASDAQ:CRXT) shares are trading lower by 52.82% at $0.85 after the company announced an upsized $30 million underwritten public offering at $1.10 per share. 

The offering is expected to close on April 27, 2022, subject to customary closing conditions. Clarus expects to use the net proceeds from the offering, together with its existing cash, for working capital and other general corporate purposes.

See Also: Why Axsome Therapeutics Stock Is Falling Today

Clarus Therapeutics focuses on the development and commercialization of oral testosterone replacement therapy in the United States.

According to data from Benzinga Pro, Clarus Therapeutics has a 52-week high of $31.24 and a 52-week low of $0.61.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.